Table of Contents Author Guidelines Submit a Manuscript
Journal of Pharmaceutics
Volume 2016 (2016), Article ID 9520361, 6 pages
http://dx.doi.org/10.1155/2016/9520361
Research Article

Novel Concepts for Drug Hypersensitivity Based on the Use of Long-Time Scale Molecular Dynamic Simulation

1Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
2Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan
3Graduate School of Information Science and Technology, Osaka University, 1-5 Yamadaoka, Suita, Osaka 565-0871, Japan

Received 4 July 2016; Accepted 3 November 2016

Academic Editor: Giuseppina De Simone

Copyright © 2016 Takahiro Murai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Musiime and A. J. Prendergast, “Can abacavir be used safely in children without HLA testing?” The Lancet HIV, vol. 3, no. 2, pp. e58–e59, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Chakravarty, S. Sharma, A. Johri, A. Chourasia, and S. Sundar, “Clinical abacavir hypersensitivity reaction among children in India,” The Indian Journal of Pediatrics, vol. 83, no. 8, pp. 855–858, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Mallal, D. Nolan, C. Witt et al., “Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir,” The Lancet, vol. 359, no. 9308, pp. 727–732, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Hetherington, A. R. Hughes, M. Mosteller et al., “Genetic variations in HLA-B region and hypersensitivity reactions to abacavir,” The Lancet, vol. 359, no. 9312, pp. 1121–1122, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Mallal, E. Phillips, G. Carosi et al., “HLA-B5701 screening for hypersensitivity to abacavir,” The New England Journal of Medicine, vol. 358, no. 6, pp. 568–579, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Pavlos, S. Mallal, D. Ostrov et al., “T Cell-mediated hypersensitivity reactions to drugs,” Annual Review of Medicine, vol. 66, pp. 439–454, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. K. D. White, W.-H. Chung, S.-I. Hung, S. Mallal, and E. J. Phillips, “Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response,” Journal of Allergy and Clinical Immunology, vol. 136, no. 2, pp. 219–234, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. Norcross, S. Luo, L. Lu et al., “Abacavir induces loading of novel self-peptides into HLA-B57: 01: an autoimmune model for HLA-associated drug hypersensitivity,” AIDS, vol. 26, no. 11, pp. F21–F29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. D. A. Ostrov, B. J. Grant, Y. A. Pompeu et al., “Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 25, pp. 9959–9964, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. P. T. Illing, J. P. Vivian, N. L. Dudek et al., “Immune self-reactivity triggered by drug-modified HLA-peptide repertoire,” Nature, vol. 486, no. 7404, pp. 554–558, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Adam, K. K. Eriksson, B. Schnyder, S. Fontana, W. J. Pichler, and D. Yerly, “Avidity determines T-cell reactivity in abacavir hypersensitivity,” European Journal of Immunology, vol. 42, no. 7, pp. 1706–1716, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. C. C. Bell, L. Faulkner, K. Martinsson et al., “T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms,” Chemical Research in Toxicology, vol. 26, no. 5, pp. 759–766, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Yun, M. J. Marcaida, K. K. Eriksson et al., “Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B58:01,” Journal of Immunology, vol. 192, no. 7, pp. 2984–2993, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. Protein Data Bank (PDB), http://pdb.org.
  15. J. Goto, R. Kataoka, H. Muta, and N. Hirayama, “ASEDock-docking based on alpha spheres and excluded volumes,” Journal of Chemical Information and Modeling, vol. 48, no. 3, pp. 583–590, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. Molecular Operatiing Environment (MOE), Chemical Computing Group, Montreal, Canada, 2013.
  17. M. J. Abraham, D. van der, E. Lindahl, and B. Hess, “GROMACS User manual version 5.0.6,” 2015, http://www.gromacs.org/.
  18. S. Matsuoka, T. Endo, N. Maruyama, H. Sato, and S. Takizawa, “The total picture of TSUBAME 2.0,” TSUBAME e-Science Journal, GSIC, Tokyo Institute of Technology, vol. 1, pp. 2–4, 2010. View at Google Scholar
  19. R. O. Dror, R. M. Dirks, J. P. Grossman, H. Xu, and D. E. Shaw, “Biomolecular simulation: a computational microscope for molecular biology,” Annual Review of Biophysics, vol. 41, no. 1, pp. 429–452, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Kass, A. M. Buckle, and N. A. Borg, “Understanding the structural dynamics of TCR-pMHC interactions,” Trends in Immunology, vol. 35, no. 12, pp. 604–612, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Knapp, S. Demharter, R. Esmaielbeiki, and C. M. Deane, “Current status and future challenges in T-cell receptor/peptide/MHC molecular dynamics simulations,” Briefings in Bioinformatics, vol. 16, no. 6, pp. 1035–1044, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. U. Omasitsa, B. Knappa, M. Neumannb et al., “Analysis of key parameters for molecular dynamics of pMHC molecules,” Molecular Simulation, vol. 34, no. 8, pp. 781–793, 2008. View at Publisher · View at Google Scholar
  23. D. Narzi, C. M. Becker, M. T. Fiorillo, B. Uchanska-Ziegler, A. Ziegler, and R. A. Böckmann, “Dynamical characterization of two differentially disease associated MHC class I proteins in complex with viral and self-peptides,” Journal of Molecular Biology, vol. 415, no. 2, pp. 429–442, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. W. J. Pichler, “Consequences of drug binding to immune receptors: immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide,” Dermatologica Sinica, vol. 31, no. 4, pp. 181–190, 2013. View at Publisher · View at Google Scholar · View at Scopus